Management of Chronic Hepatitis B: Status and Challenges beyond Treatment Guidelines

ABSTRACT

Several national and international guidelines have been published in the last years focusing on the problem of how to best treat patients with chronic hepatitis B virus (HBV) infection. Therapy with interferon or nucleos(t)ide analogues has been shown to be most effective in suppressing HBV deoxyribonucleic acid (DNA) levels and preventing fibrosis progression herby also reducing the risk of hepatocellular carcinoma (HCC). However even suppression of viral replication below the limit of detection does not prevent HCC development although fibrosis can be stopped. Thus, improvement of therapeutic strategies and the establishment of more sensitive markers that may help to decide when therapy should be initiated and stopped remain important goals in hepatitis research. The present review discusses several major issues in this respect such as strategies to identify the optimal time point for treatment indication and end of therapy. It also concentrates on questions and queries that have to do with the interpretation of viral parameters like HBsAg quantification, HBV genotypes, and HBeAg, or the characterization of risk patients prone to develop fatal sequel of the HBV infection.

Antiviral therapy - hepatitis B genotype - HBsAg quantification - hepatocellular carcinoma prevention - interferon-alfa - nucleoside analogues - nucleotide analogues

REFERENCES

• 1 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.  J Viral Hepat. 2004;  11(2) 97-107
• 2 Iloeje U H, Yang H I, Su J, Jen C L, You S L, Chen C J. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.  Gastroenterology. 2006;  130(3) 678-686
• 3 Chen C J, Yang H I, Su J REVEAL-HBV Study Group et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  JAMA. 2006;  295(1) 65-73
• 4 Paterlini P, Gerken G, Nakajima E et al.. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen.  N Engl J Med. 1990;  323(2) 80-85
• 5 Donato F, Gelatti U, Limina R M, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence.  Oncogene. 2006;  25(27) 3756-3770
• 6 Chang M H, Chen C J, Lai M S Taiwan Childhood Hepatoma Study Group et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.  N Engl J Med. 1997;  336(26) 1855-1859
• 7 Liaw Y F, Sung J J, Chow W C Cirrhosis Asian Lamivudine Multicentre Study Group et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351(15) 1521-1531
• 8 Di Marco V, Marzano A, Lampertico P Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.  Hepatology. 2004;  40(4) 883-891
• 9 Craxì A, Di Bona D, Cammà C. Interferon-alpha for HBeAg-positive chronic hepatitis B.  J Hepatol. 2003;  39(Suppl 1) S99-S105
• 10 Poynard T, Massard J, Rudler M et al.. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials.  Gastroenterol Clin Biol. 2009;  33(10-11) 916-922
• 11 Shim J H, Lee H C, Kim K M et al.. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.  J Hepatol. 2010;  52(2) 176-182
• 12 Kim W R, Terrault N A, Pedersen R A et al.. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.  Gastroenterology. 2009;  137(5) 1680-1686
• 13 Wedemeyer H, Hofmann W P, Lueth S et al.. [ALT screening for chronic liver diseases: scrutinizing the evidence].  Z Gastroenterol. 2010;  48(1) 46-55
• 14 Chen J D, Yang H I, Iloeje U H Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.  Gastroenterology. 2010;  138(5) 1747-1754
• 15 Simonetti J, Bulkow L, McMahon B J et al.. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus.  Hepatology. 2010;  51(5) 1531-1537
• 16 Cornberg M, Protzer U, Dollinger M M et al.. [Prophylaxis, diagnosis and therapy of hepatitis-B-virus- (HBV-) infection: upgrade of the guideline, AWMF-Register 021/011].  Z Gastroenterol. 2007;  45(6) 525-574
• 17 European Association for the Study of the Liver . EASL Clinical Practice Guidelines: management of chronic hepatitis B.  J Hepatol. 2009;  50(2) 227-242
• 18 Liaw Y F, Leung N, Kao J H for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.  Hepatol Int. 2008;  2(3) 263-283
• 19 Lok A S, McMahon B J. Chronic hepatitis B: update 2009.  Hepatology. 2009;  50(3) 661-662
• 20 Kumar M, Sarin S K, Hissar S et al.. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.  Gastroenterology. 2008;  134(5) 1376-1384
• 21 Papatheodoridis G V, Manesis E K, Manolakopoulos S et al.. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?.  Hepatology. 2008;  48(5) 1451-1459
• 22 Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years.  Gut. 2008;  57(1) 84-90
• 23 Wong G L, Wong V W, Choi P C, Chan A W, Chan H L. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B.  Aliment Pharmacol Ther. 2010;  31(10) 1095-1103
• 24 Fung J, Lai C L, Chan S C et al.. Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis.  Am J Gastroenterol. 2010;  105(5) 1116-1122
• 25 Kim S U, Ahn S H, Park J Y et al.. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis.  J Clin Gastroenterol. 2009;  43(3) 267-271
• 26 Werle-Lapostolle B, Bowden S, Locarnini S et al.. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.  Gastroenterology. 2004;  126(7) 1750-1758
• 27 Wursthorn K, Lutgehetmann M, Dandri M et al.. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.  Hepatology. 2006;  44(3) 675-684
• 28 Volz T, Lutgehetmann M, Wachtler P et al.. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.  Gastroenterology. 2007;  133(3) 843-852
• 29 Jaroszewicz J, Calle Serrano B, Wursthorn K et al.. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV) infection: a European perspective.  J Hepatol. 2010;  52(4) 514-522
• 30 Nguyen T, Thompson A J, Bowden S et al.. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.  J Hepatol. 2010;  52(4) 508-513
• 31 Brunetto M R, Oliveri F, Colombatto P et al.. Use of HBsAg serum levels help to distinguish active from inactive HBV genotype D carriers.  Gastroenterology. 2010;  139(2) 483-490
• 32 Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission.  Jpn J Exp Med. 1987;  57(4) 231-236
• 33 Norder H, Arauz-Ruiz P, Blitz L, Pujol F H, Echevarria J M, Magnius L O. The T(1858) variant predisposing to the precore stop mutation correlates with one of two major genotype F hepatitis B virus clades.  J Gen Virol. 2003;  84(Pt 8) 2083-2087
• 34 Arauz-Ruiz P, Norder H, Robertson B H, Magnius L O. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America.  J Gen Virol. 2002;  83(Pt 8) 2059-2073
• 35 Stuyver L, De Gendt S, Van Geyt C et al.. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.  J Gen Virol. 2000;  81(Pt 1) 67-74
• 36 Simmonds P, Midgley S. Recombination in the genesis and evolution of hepatitis B virus genotypes.  J Virol. 2005;  79(24) 15467-15476
• 37 Thakur V, Guptan R C, Kazim S N, Malhotra V, Sarin S K. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent.  J Gastroenterol Hepatol. 2002;  17(2) 165-170
• 38 Westland C E, Yang H, Delaney IV W E 437 and 438 Study Teams et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.  Hepatology. 2003;  38(1) 96-103
• 39 Lindh M, Andersson A S, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus—large-scale analysis using a new genotyping method.  J Infect Dis. 1997;  175(6) 1285-1293
• 40 Chu C J, Keeffe E B, Han S H et al.. Hepatitis B virus genotypes in the United States: results of a nationwide study.  Gastroenterology. 2003;  125(2) 444-451
• 41 Naumann H, Schaefer S, Yoshida C F, Gaspar A M, Repp R, Gerlich W H. Identification of a new hepatitis B virus (HBV) genotype from Brazil that expresses HBV surface antigen subtype adw4.  J Gen Virol. 1993;  74(Pt 8) 1627-1632
• 42 Norder H, Couroucé A M, Magnius L O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes.  Virology. 1994;  198(2) 489-503
• 43 Ohkawa K, Hiramatsu N, Mochizuki K et al.. Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response.  J Gastroenterol Hepatol. 2001;  16(9) 1009-1014
• 44 Kato H, Orito E, Gish R G et al.. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F).  J Virol. 2002;  76(12) 6131-6137
• 45 Sánchez-Tapias J M, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients.  Gastroenterology. 2002;  123(6) 1848-1856
• 46 Kew M C, Kramvis A, Yu M C, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans.  J Med Virol. 2005;  75(4) 513-521
• 47 Orito E, Ichida T, Sakugawa H et al.. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan.  Hepatology. 2001;  34(3) 590-594
• 48 Kobayashi M, Arase Y, Ikeda K et al.. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C.  J Gastroenterol. 2002;  37(1) 35-39
• 49 Mommeja-Marin H, Mondou E, Blum M R, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature.  Hepatology. 2003;  37(6) 1309-1319
• 50 Schiff E, Simsek H, Lee W M et al.. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.  Am J Gastroenterol. 2008;  103(11) 2776-2783
• 51 El-Serag H B, Rudolph K L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.  Gastroenterology. 2007;  132(7) 2557-2576
• 52 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362(9399) 1907-1917
• 53 Beasley R P, Hwang L Y, Lin C C, Chien C S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.  Lancet. 1981;  2(8256) 1129-1133
• 54 Ishikawa T, Ichida T, Yamagiwa S et al.. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis.  J Gastroenterol Hepatol. 2001;  16(11) 1274-1281
• 55 Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection.  J Gastroenterol Hepatol. 2004;  19(6) 670-675
• 56 Niederau C, Heintges T, Lange S et al.. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med. 1996;  334(22) 1422-1427
• 57 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology. 1999;  29(3) 971-975
• 58 van Zonneveld M, Honkoop P, Hansen B E van ZM et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.  Hepatology. 2004;  39(3) 804-810
• 59 Lin S M, Yu M L, Lee C M et al.. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.  J Hepatol. 2007;  46(1) 45-52
• 60 Matsumoto A, Tanaka E, Rokuhara A the Inuyama Hepatitis Study Group et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients.  Hepatol Res. 2005;  32(3) 173-184
• 61 Yuen M F, Seto W K, Chow D H et al.. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.  Antivir Ther. 2007;  12(8) 1295-1303
• 62 Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.  Gastroenterology. 2007;  133(5) 1445-1451
• 63 van Bömmel F, de Man R A, Wedemeyer H et al.. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.  Hepatology. 2010;  51(1) 73-80
• 64 Papatheodoridis G V, Manolakopoulos S, Touloumi G et al.. Risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with or without cirrhosis treated with oral antivirals: results of the nationwide HEPNET Greece cohort study. Paper presented at: 60th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) October 30–November 3, 2009 Boston, MA;
• 65 Yuen M F, Wong D K, Fung J et al.. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.  Gastroenterology. 2008;  135(4) 1192-1199
• 66 Gane E J. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B.  Hepatol Int. 2008;  2(3) 304-307
• 67 Fried M W, Piratvisuth T, Lau G K et al.. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.  Hepatology. 2008;  47(2) 428-434
• 68 Hansen B E, Buster E H, Steyerberg E W, Lesaffre E, Janssen H L. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment.  J Med Virol. 2010;  82(7) 1135-1142
• 69 ter Borg M J, van Zonneveld M, Zeuzem S HBV 99-01 Study Group et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.  Hepatology. 2006;  44(3) 721-727
• 70 Liaw Y F. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.  Liver Int. 2009;  29(Suppl 1) 100-107
• 71 Hsu Y S, Chien R N, Yeh C T et al.. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.  Hepatology. 2002;  35(6) 1522-1527
• 72 Chu C M, Yeh C T, Lee C S, Sheen I S, Liaw Y F. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion.  J Clin Microbiol. 2002;  40(1) 16-21
• 73 Sherman M. Predicting survival in hepatitis B.  Gut. 2005;  54(11) 1521-1523
• 74 Yuen M F, Yuan H J, Wong D K et al.. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.  Gut. 2005;  54(11) 1610-1614
• 75 Reijnders J G, Perquin M J, Zhang N, Hansen B E, Janssen H L. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.  Gastroenterology. 2010;  139(2) 491-498
• 76 Fung J, Lai C L, Tanaka Y et al.. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.  Am J Gastroenterol. 2009;  104(8) 1940-1946, quiz 1947
• 77 Wong V W, Wong G L, Yan K K et al.. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.  Hepatology. 2010;  51(6) 1945-1953
• 78 Thompson A J, Nguyen T, Iser D et al.. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.  Hepatology. 2010;  51(6) 1933-1944
• 79 Hadziyannis S J, Sevastianos V, Rapti I N, Tassopoulos N C. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in chronic HBeAg negative chronic hepatitis B. Paper presented at: 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) October 27–31, 2006 Boston, MA;
• 80 Heathcote E, Gane E J, de Man R A et al.. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis. Abstract presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) October 30–November 1, 2009 Boston, MA; Abstract 483
• 81 Chang T T, Lai C L, Kew Yoon S et al.. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.  Hepatology. 2010;  51(2) 422-430
• 82 Gish R G, Chang T T, Lai C L et al.. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.  J Viral Hepat. 2010;  17(1) 16-22
• 83 Marcellin P, Bonino F, Lau G K Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.  Gastroenterology. 2009;  136(7) 2169-2179 e1-e4
• 84 Marcellin P, Piratvisuth T, Brunetto M et al.. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a+/−lamivudine: results of 5-year post-treatment follow up. The mentioned citation is the official citation recommendation of the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) April 22–26, 2009 Copenhagen, Denmark;
• 85 Brunetto M R, Moriconi F, Bonino F et al.. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.  Hepatology. 2009;  49(4) 1141-1150
• 86 Manesis E K, Hadziyannis E S, Angelopoulou O P, Hadziyannis S J. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels.  Antivir Ther. 2007;  12(1) 73-82
• 87 Reijnders J G, Rijckborst V, Sonneveld M J et al.. HBSAG levels during antiviral therapy for chronic hepatitis B: peginterferon versus entecavir.  J Hepatol. 2010;  52(Suppl 1) S395
• 88 Moucari R, Mackiewicz V, Lada O et al.. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.  Hepatology. 2009;  49(4) 1151-1157
• 89 Moucari R, Korevaar A, Lada O et al.. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.  J Hepatol. 2009;  50(6) 1084-1092
• 90 Jung Y K, Kim J H, Lee Y S, Lee H J, Yoon E, Jung E S et al.. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis b e antigen-positive patients receiving entecavir.  J Clin Gastroenterol. 2010;  44(9) 653-657
• 91 Gane E, Heathcote E J, Marcellin P et al.. HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis b following 3 years of tenofovir disoproxil fumarate (TDF) treatment.  J Hepatol. 2010;  52(Suppl 1) S388
• 92 Wiegand J, Wedemeyer H, Finger A et al.. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels.  Antivir Ther. 2008;  13(4) 547-554
• 93 Cai W, Xie Q, An B et al.. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.  J Clin Virol. 2010;  48(1) 22-26
• 94 Wiegand J, Hasenclever D, Tillmann H L. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.  Antivir Ther. 2008;  13(2) 211-220
• 95 Raimondi S, Maisonneuve P, Bruno S, Mondelli M U. Is response to antiviral treatment influenced by hepatitis B virus genotype?.  J Hepatol. 2010;  52(3) 441-449
• 96 Buster E H, Hansen B E, Lau G K et al.. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.  Gastroenterology. 2009;  137(6) 2002-2009
• 97 Inoue J, Ueno Y, Wakui Y, Niitsuma H, Fukushima K, Yamagiwa Y et al.. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.  J Viral Hepat. 2010;  , March 28 [Epub ahead of print]
• 98 Damerow H, Yuen L, Wiegand J et al.. Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern.  J Med Virol. 2010;  82(11) 1850-1858
• 99 Berg T, Benhamou Y, Calleja J L, Levrero M, Johnson W, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union.  J Viral Hepat. 2010;  17(9) 624-630
• 100 Chen Y C, Chu C M, Liaw Y F. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.  Hepatology. 2010;  51(2) 435-444
• 101 Bortolotti F, Jara P, Barbera C et al.. Long term effect of alpha interferon in children with chronic hepatitis B.  Gut. 2000;  46(5) 715-718
• 102 D'Antiga L, Aw M, Atkins M, Moorat A, Vergani D, Mieli-Vergani G. Combined lamivudine/interferon-alpha treatment in “immunotolerant” children perinatally infected with hepatitis B: a pilot study.  J Pediatr. 2006;  148(2) 228-233
• 103 Park J Y, Park Y N, Kim D Y et al.. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels.  J Viral Hepat. 2008;  15 615-621
• 104 Veldhuijzen I K, Toy M, Hahné S J et al.. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.  Gastroenterology. 2010;  138(2) 522-530
• 105 Toy M, Veldhuijzen I K, de Man R A, Richardus J H, Schalm S W. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B.  Hepatology. 2009;  50(3) 743-751
• 106 Buti M, Brosa M, Casado M A, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.  J Hepatol. 2009;  51(4) 640-646
• 107 Zeuzem S, Gane E, Liaw Y F et al.. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.  J Hepatol. 2009;  51(1) 11-20
• 108 Brown Jr R S, Buti M, Goodwin R G, Zhang S, Fagan E, Hepatitis B. Hepatitis B Virus (HBV) drugs in pregnancy: findings from the antiretroviral pregnancy registry.  J Hepatol. 2009;  50(Suppl 1) S4
• 109 Bahra M, Seehofer D, Neumann U P, Berg T. Hepatitis B und C Reinfektion: Prophylaxe und Therapie.  Der Gastroenterologe. 2009;  4 526-539
• 110 Mayerat C, Mantegani A, Frei P C. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?.  J Viral Hepat. 1999;  6(4) 299-304
• 111 Kobayashi M, Arase Y, Ikeda K et al.. Clinical features of hepatitis B virus genotype A in Japanese patients.  J Gastroenterol. 2003;  38(7) 656-662
• 112 Schaefer S. Hepatitis B virus: significance of genotypes.  J Viral Hepat. 2005;  12(2) 111-124
• 113 Tsubota A, Arase Y, Ren F, Tanaka H, Ikeda K, Kumada H. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw.  J Med Virol. 2001;  65(2) 257-265
• 114 Sumi H, Yokosuka O, Seki N et al.. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease.  Hepatology. 2003;  37(1) 19-26
• 115 Yuen M F, Sablon E, Yuan H J et al.. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma.  Hepatology. 2003;  37(3) 562-567
• 116 Ding X, Mizokami M, Yao G et al.. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China.  Intervirology. 2001;  44(1) 43-47
• 117 Sugauchi F, Chutaputti A, Orito E et al.. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand.  J Gastroenterol Hepatol. 2002;  17(6) 671-676
• 118 Kao J H, Chen P J, Lai M Y, Chen D S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.  Gastroenterology. 2000;  118(3) 554-559
• 119 Wai C T, Fontana R J, Polson J US Acute Liver Failure Study Group et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States.  J Viral Hepat. 2005;  12(2) 192-198